Business Wire

Celltrion Healthcare Hosts Forum with Patient Advocacy Groups to Provide Information on the Use of Biosimilars in Oncology

Jaa

To coincide with the ESMO 2018 Congress in Munich, Germany, Celltrion Healthcare invited perspective from experts including a physician and pharmacist to provide information to patient advocacy groups on the history of biosimilars, how they are tested and approved, their cost saving benefit and the wealth of clinical evidence already available on their use in order to improve understanding of biosimilars.

The introduction of biosimilars in the treatment of cancer has the potential to reduce pressure on healthcare budgets and increase access to other innovative treatments or more potent regimens. This is achieved by offering more cost-effective alternatives to the reference medicinal products and by increasing competition in the market.

Breast cancer is the most common cancer in women worldwide and accounts for a quarter of all cancer diagnoses in women.1 For the benefits of biosimilar use to be realised in oncology, and in the treatment of breast cancer, barriers to their uptake need to be addressed. Some of the barriers include, lack of familiarity in prescribing biosimilars amongst oncologists and low understanding of what biosimilars are amongst patients.

Oncologists and oncology nurses need to be better educated about biosimilars, the development process and the steps in the regulatory pathway to feel confident in prescribing and administering them and to provide well-informed advice and support to their patients.

The regulatory process for biosimilars is significantly more advanced than that for generics, with trials assessing safety and efficacy required alongside pharmacodynamic and pharmacokinetic studies, although this is not widely understood.

The introduction of biosimilars in oncology can benefit patients by allowing access to new innovative treatments that would otherwise not be cost-effective. Patients can be concerned by changes to their treatment so must be well informed about their treatments and understand the rationale for any switch to biosimilars.

As the wealth of experience of biosimilars has built up, confidence in their use has increased. Professional groups such as the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) both recognise the benefits of biosimilars in oncology care and have published guidance on their use and value.

“The perception of biosimilars amongst stakeholders has changed positively as more evidence has become available,” said Prof. Stebbing, Faculty of Medicine, Department of Surgery and Cancer, Imperial College London. “Professional groups such as ESMO recognise the opportunity biosimilars provide in obtaining optimal clinical outcomes whilst controlling the cost of cancer treatments. Guidance from groups such as these gives physicians confidence to prescribe them”.

“We are at a turning point in the use of biosimilars as the benefit they bring to healthcare systems is beginning to be universally recognised,” said Mr HoUng Kim, Head of Strategy and Operations Division, Celltrion Healthcare. “This needs to be replicated in the field of oncology, so we can ensure patients worldwide can get access to new treatment regimens through the use of high quality, more cost-effective biosimilars”.

--- Ends ---

Notes to editors:

About Herzuma ® (CT-P6, biosimilar trastuzumab)

CT-P6 is a monoclonal antibody (mAb) – a protein designed to recognise and bind to a specific structure or antigen in the body. CT-P6 has been designed to bind with high affinity and specificity to the extracellular domain of human epidermal growth factor receptor (HER2).

HER2 is found to be overexpressed and/or amplified in about 15-20% of patients with the diseases for which reference trastuzumab is indicated. By binding to HER2 receptor binding domains on the tumor cells, trastuzumab inhibits proliferation of HER2 overexpressing tumour cells.

Celltrion has carried out extensive studies between CT-P6 and reference trastuzumab to establish that they are highly similar in physicochemical and biological attributes. Studies have also demonstrated comparability in terms of efficacy, pharmacokinetics, pharmacodynamics, immunogenicity and safety.

Herzuma® is a biosimilar to Herceptin®2, a biologic drug developed by Genentech and marketed by Roche. Herceptin® is a blockbuster drug which had worldwide sales of CHF 6.8 billion (US$6.8billion) in 2016, of which CHF 2.1 billion (US$2.1 billion) was in European sales. 3

CT-P6 is also currently under review by the FDA but not yet an approved product in the U.S.

About Celltrion Healthcare

Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Remsima®/ Inflectra® (CT-P13, biosimilar infliximab) which is the world’s first monoclonal antibody (mAb) biosimilar, received EMA and FDA approval, respectively. Truxima® (CT-P10, biosimilar rituximab) and Herzuma® (CT-P6, biosimilar trastuzumab) received EMA approval. Celltrion Healthcare’s products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavors to offer high-quality cost-effective solutions through an extensive global network that spans more than 120 different countries. For more information please visit: http://www.celltrionhealthcare.com/

References

1 World Cancer Research Fund. Global cancer incidence. Available at https://www.wcrf.org/dietandcancer/cancer-trends/worldwide-cancer-data [Last accessed October 2018].

2 Herceptin® is a registered trademark of Genentech Inc.

3 Roche Financial Report 2016. Available at: https://static.roche.com/annual-report-2016/_downloads/roche_full_financial_report16.pdf [Last accessed October 2018].

Contact information

Hanover Communications
Emma Gorton
egorton@hanovercomms.com
+44 203 817 6791
or
Georgia Featherston
gfeatherston@hanovercomms.com
+44 203 817 6718

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Kenetic Bucks Crypto Market Trend with YTD 77% Returns in Investment Portfolio14.11.2018 10:37Tiedote

Kenetic, a blockchain investment and advisory firm based in Hong Kong, has revealed that its proprietary investment portfolio has recorded year-to-date returns of 77 percent as of October 31, 2018, against a backdrop of major losses in the cryptocurrency market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181113006323/en/ After hitting its record high in December 2017, Bitcoin has fallen over 50 percent in 2018 and the overall crypto market is down around 65%. Kenetic’s proprietary investment portfolio is comprised of its best ideas that have undergone thorough due diligence by its experienced investment team. Its alpha-generating strategies are largely focused on early stage investments, catalyst driven events and macro themes, complemented by prudent risk management and proprietary in-house trading tools. “As active leaders in the global blockchain community, we see where the strongest investment opportunities lie and r

Smiths Detection State-of-the-Art Checkpoint Lanes Chosen for Israeli Airports14.11.2018 10:30Tiedote

Smiths Detection and its local distributor, Eastronics, have been selected by the Israel Airport Authority (IAA) to supply 32 advanced checkpoint lanes for Ben Gurion Airport and the new Ramon International Airport, which is due to open in 2019. These latest, highly functional lane designs from Smiths Detection incorporate automated tray return and diversion and were developed to improve operational efficiency and passenger experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181113005810/en/ “Automation plays a key role in streamlining screening by literally keeping things moving and the result is increased throughput, lower per capita costs and a passenger friendly process,” explained Tony Tielen, Vice President EMEA, at Smiths Detection. “With the help of Eastronics, we were delighted to be able to meet IAA’s stringent requirements for this extensive project, which could have a significant impact on maintaining flow

CHTF 2018 Opens, Gathering Global Enterprises and Entrepreneurs14.11.2018 09:00Tiedote

The 20th China Hi-Tech Fair (CHTF 2018) kicked off at the Shenzhen Convention and Exhibition Center on November 14, 2018. By showcasing cutting-edge high-tech products and technologies of enterprises and institutions from around the world, CHTF 2018 remained a trend setter in the high-tech industry. A large number of technology companies have emerged from CHTF in the past two decades. In its 20th year, CHTF 2018 attracted the world's top experts and scholars, and gathered multinational corporations, Fortune 500 companies and unicorn enterprises to showcase the latest technical developments. Chinese giants included China Mobile, China Unicom, China Telecom, China Electronics, CRRC; multinational companies included Suez, Foxconn, Ricoh, Baidu, Tsinghua Tongfang, TCL, Sogou, BOE; unicorn enterprises included SenseTime, iQiyi, Royale, Orbbec, Qiniu Cloud, BITMAIN, etc. In addition, three leading AI chip companies, namely Cambrian, Horizon Robotics and Deephi Tech, were also involved. The C

Kalray Releases the Kalray Neural Network 3.0 (KaNN) to Accelerate Artificial Intelligence Application Development13.11.2018 21:26Tiedote

Kalray (Euronext Growth Paris – ALKAL), a pioneer in processors for new intelligent systems, today announced the launch of the Kalray Neural Network 3.0 (KaNN), a platform for Artificial Intelligence application development. KaNN allows developers to seamlessly port their AI-based algorithms from well-known machine learning frameworks including Caffe®, Torch® and TensorFlow® onto Kalray’s Massively Parallel Processor Array (MPPA®) intelligent processor. Artificial Intelligence is at the heart of a growing number of applications such as autonomous vehicles, intelligent storage servers, data centers, robotics, drones, and more. Kalray’s manycore MPPA® intelligent processor has been architected from the ground up to meet the incredible performance requirements of such advanced applications. However, it is crucial to provide an easy way for AI developers to seamlessly support the AI networks they develop. “The Kalray MPPA® intelligent processor is capable of processing massive amounts of d

Sharjah International Book Fair 2018 Celebrates Reading and Culture with 2.23 Million Visitors13.11.2018 21:17Tiedote

The world’s third largest celebration of the written word, the Sharjah International Book Fair (SIBF), has put up yet another record performance in its 37th annual edition. Themed ‘A Tale of Letters’, the event was a dream come true occasion for book lovers, who had access to 20 million books, all under one roof. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181113006044/en/ Sharjah International Book Fair 2018 - Provided by Sharjah Book Authority (Photo: Business Wire) Organised by the Sharjah Book Authority (SBA) in the emirate of Sharjah, cultural capital of the United Arab Emirates (UAE), SIBF 2018 witnessed a footfall of 2.23 million visitors in 11 days, including 230,000 school students who poured in from around the country. The Sharjah International Book Fair hosted 1,874 publishers from 77 countries who brought in 1.6 million titles, 80,000 of which were seen at the fair for the first time. It also offered its stage

Communications and Business Transformation Strategist Brian Ellner Joins BCW to Lead U.S. Corporate Practice13.11.2018 21:00Tiedote

BCW (Burson Cohn & Wolfe), a leading global communications agency, announced today that Brian Ellner has joined as Executive Vice President, Global Corporate Solutions, responsible for leading and growing BCW’s U.S. Corporate Practice. Ellner takes on the role previously held by Aranthan “AJ” Jones II, who will now lead the firm’s Public Affairs and Crisis Practice in the U.S. “Corporations are navigating an increasingly complex world where their reputations are tied not only to their own performance but also to their behavior on topics like climate, gender pay equity, visa status, diversity and inclusion and the environment,” said Chris Foster, President, North America, BCW. “Brian has deep experience helping clients build and protect their reputations, manage business transformation and create authentic social purpose engagements. He is a seasoned strategic counselor and power player in the New York business world and will bring our clients and our business clear opportunities for gr

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme